Sondra. Good and fourth you, year-end welcome our XXXX Thank to everyone, report. quarter morning, and
We detail, financial share we strategic financial way will And our reporting in priorities are new results the finished guidance in addition we our and year. XXXX to the happy with for provide XXXX.
to XXXX We and specific headwinds have of we growth about a a to put market. lot return positive as reasons behind XXXX us, we the see bioprocessing for be
exchange headwind $XXX.X in and the to quarter of conditions fourth quarter pleased revenue the year a enabled differentiation, quarter. to delivering us market versus execution year. of deliver team excellent our growth ex-COVID we achieved full guidance, November have in I'm share better million our $XXX.X revenue of previous Product XX% the a midpoint by the and despite $X.X that million fourth revenue million rate
and to equipment, orders also that were Our quarter since very it had fourth from been quarter with key quarter outpaced X In in straight order strong strong recover. delighted we've CDMOs was XXXX, performance sectors X, quarter the have the were sixth the intake revenue. by the we of non-COVID that and slower market orders highest
double our sales this and XXXX. even With enter rebound up After we digits a continues our positioned well an to quarter as in quarter with and grow, better sequentially. we momentum are as X, great business funnel orders CDMO high had
for similar sales CDMO at year We high fact, up our was finish, very equipment. both XXXX and a growth CDMO pattern full single saw strong that In to thanks digits. similar Pharma,
up equipment full Thanks was X% than that sales and quarter equipment, for Following orders to similar a important another X, year strong and our finish, consumables was growth respectively. solid both more XX% standout in the fourth both equipment sales with quarter sequentially. and up XX%, XXXX
had acquired excellent record Filtration and point quarter sales level, since finally, momentum a double-digit another in both of we had key Analytics technology And both sales franchise a as XXXX orders both and CTech low quarter, from view, XXXX. we the orders revenue new and a has order in new and with been modalities accounts great and year build launches. in At growth for with
and our of I Before our fantastic adjusting line headwinds. teams XXXX, portfolio. in currency in excluding revenue uniqueness huge our with to entering initial demonstrates and in the full year in and would to and into was growth fact, more headwinds our And execution additional revenue say February for detail, that XXXX, protein managing like the deliver China X% the COVID of in outlook considering restatement the
on reflect the the I'm year, how we also addition results, very market the and forward I Repligen to the strategic of beginning with our executed in team the on set X full pleased the When of priorities XXXX. at momentum
quarters. up has through At probability to the First, replenished XX funnel quarter the year, their we end was And than XX% December, increased orders, QX very with probability the our versus of our the even end over XX% high strong last driving of highest level funnel. funnel the fourth orders greater XXXX.
our organization, Our well extended have visibility. key our management account in team XXXX, top at and training accounts and leads done CDMO including greatest pharma portfolio our improving new sales
Of resin the from through resin RNA In products in-line and resin bench acquired the game-changing in first scale solvents. or RNA remove measurement. without This for transcribed prepacked our from the single-use in sold launched OPUS we CrossFlow in concentration we production the newly Next, Tantti automated new AviPure heat only double-stranded December, our affinity fully RNA first note, it system remarkable we May, TFF columns. launched protein system, RSXX differentiated bid business impurity GMP RPM is to using several launched our double-stranded XXXX. with that is
and to XX% We These the business grow innovative for about differentiated add helping in and that other market. launches from needs technologies, in our to XXXX differentiated are are our which a above solution cornerstone portfolio. highly customers' estimate of unmet come offering
new was wins modalities. on priority Our third to further our in build
have above approximately double now now represents low accounts new We and digits sales of million. modalities increased Our total $X our XX% with revenue. have XX in sales
preparing XXXX. our gains. the integrated of integration we we quarter launch single-use for launch with of our was further mixer and to consolidation new X And discipline have strengthened and Metenova single-use successful control We teams priority Through mixers rooftop our are finally, of and team, margin. actions, select Metenova planning in next in The management our targeted expanded achieved formally successfully additional fleet cost restructuring technologies. and productivity operation the
XX.X%, finish This and margin EBITDA at has to operating adjusted XX.X% at XX.X%. the year enabled QX us at margin adjusted adjusted gross with margin
expanded adjusted it by margin points. basis our gross full Jason discuss XXX will the successfully For we further. year,
and our onboarded in services, product us to leaders to We from diversity fit years several addition across management of growth. and of enable includes, XXXX, and but Repligen In further to priorities for sales. stated experience believe has industry This the our we bench the become to strengthen well for position growth. us is have talent not quality, will experienced limited today
So quarter and year to revenue moving our now and full fourth orders performance.
fourth our million by third As in quarter you from for $XXX.X million morning, and saw reach $XX release year. the up $XXX.X XXXX sales stepped nearly full quarter million to press this
the our with million higher-than-anticipated of highest X was XXXX, in of $X.X headwinds the quarter currency year. million quarter even quarter Excluding and COVID, sales in for this in X $X.X
growth. we and X% XX% delivered sequential revenue QX COVID, Excluding of
expected, X%. XXXX year, in full the non-COVID revenue growth came up as For
orders. to Moving
Our strong X, both opportunity year-over-year. funnel XX%, up were sequentially delivered. Orders exceptionally quarter and in
As intake I order was of this second mentioned, highest quarter since the the had we've XXXX.
over proteins, total For with up up except all X% franchises, XXXX, the were XX%. full orders year
X%. During the quarter, and orders the orders outpaced sales sales year, full non-COVID by X% by for outpaced
to segments, high strong X, single and another relates were by digit, quarter was account our it mid-single sales digits up quarter In excluding quarter COVID up key for Pharma customer supported X As sequentially focus. year-over-year. pharma
pharma versus X record up reached level and orders X approximately were Quarter XXXX. a of quarter XX%
were and up X full similar up on challenge was X landing pharma, XX% is quarter with Though XXXX. revenue in biotech. about sales, XX% over HX sequentially. our year par pharma low increased for XX% sales between remaining were and quarter While the orders order Within small HX,
a in we confirmation continue XXXX, continue durably business monitor the standout and improved CDMO half well the a more for was need we will see first very as several We of that funding has going in this the are pharma has whole though quarters, hoping to quarter. Where now environment. will to been
revenue This more the from grew year-over-year. is CDMOs. the ecosystem. up the higher. XX% market CDMO year-over-year. case CDMO and reflects since XXXX, of the highest higher for with sequentially year nearly was also sequentially X We than that orders Orders were more and X and the X HX recovery sales This about health Quarter accelerate than of XX% through both excluding Tier orders and the X overall really CDMOs of X Tier quarter illustrates segment quarter than critical in XX% activity HX saw XX% XX% XX% a COVID.
XX have Moving Consumable was had positive several in fourth was in trend now fourth the consistently equipment quarters, quarter. and standout to at showed revenues through remained the strong consumable strong non-COVID a the also healthy than XXXX. another consumables year quarter and performance highest improvement product X with year-over-year. nearly type, and the whereas for XX% the quarter level for up order XX% last more the quarters, quarter of and Quarter in highest year-over-year was sequentially XX% up since X
consumable and increased design as our to attached commercial we to systems. late particularly the single-use our are by in excited traction We have as due phase ATF products well in
Moving more XX% saw year-over-year. quarter both sequentially in up to and equipment. more rebound with sales orders X accelerated than XX% than X quarter The we in and
level. to to with ATF equipment, higher for This at companies approximately reached well chrome TFF our of year as as And start COVID, QX a XX% Excluding the than it a majority our and pharma record systems. our implementing the orders large HX. reflects success we was a HX CDMO slower orders saw starting controllers equipment platform and while in rebound
place PAT systems, are of in-line market, quality with coupled about future, can top our excited the really that considering and system the a flow Our disrupting consumable we're technology every sales. generate flow
top level were Moving and Process performers Filtration business Analytics. fourth The to franchise now the quarter in highlights.
we and its been strong continued return periods. we played impacted in by turn expect quarter, Proteins equipment we year a after Filtration anticipated, bit fourth having results. to XXXX a in in through the up year's the While prior positive Analytics, softness a trend growth this the better in saw than out
our the and revenue strong down fourth Drilling across XX% Filtration, in performance with total and full Finally, quarter. ex in largest for million XX% was X% The portfolio, diverse. Filtration in pickup nearly our year-over-year fourth each up chromatography the saw nice our year, representing sales starting most of and up COVID franchise were XX% the Filtration a and revenue. for quarter revenues $XXX the sales the year. exceeded
up were [indiscernible] finished XX% quarter above up and year a portfolio, us about the Filtration XXXX. both growth had sequentially great XX%, orders setting for line and well Within the in year-over-year, top with fourth
Excluding quarters. filtration COVID, the in level record were were also XX QX orders Systems orders and a quarter kit X. of last the highest at flow
performance quarter different filtration great with strong X business So for overall, product in our components the launches. and contribution from new of
for continued expectation XX.X% will XX% to this excluding reported up As COVID. our momentum and up a and XXXX XXXX, strength is on we XX.X% that to see exiting X% franchise basis be
fourth In of the in Chromatography and represented in chromatography, our XX% million full total year-over-year approximately year. the X% of revenues down revenue for were XX% $XXX up revenue XXXX. quarter
decline year previously, down and we of XXXX, for versus prepacked but and sales pharma more leveraging on digit OPUS up full converting On powerful to was differentiation. large the mix organization XXXX. orders, focus quarter, mid-double systems, capitalizing companies chrome the mentioned chrome technology slightly our for higher will the column columns was year sales. impacted In full resin As on by
in which million, the of XXXX, expectations. range growth In was of XXXX, revenue was $XX For actually than XX%. decline our our to Chromatography XX%, we better XX% proteins expect revenue initial a
protein has that a full the had level. become tailwind orders wins custom down we OEM almost been a with We for year will in It to the year, we reset For more ligand the believe XXXX minimum numerous future. XX% ligand sales. demand collected true resin than and
and for RNA needs double-stranded resin resins unmet seeing additional look are in for introducing purification December XXXX. healthy already launched demand [indiscernible] forward We in to the
Our to this ownership close growth our future. and with collaboration combined on more to back of offering Avitide XX% us control [indiscernible] to XXXX for Purolite XX% with emerging should in enable franchise antibodies get and monoclonal modalities
XX% Finally, X% our up year-on-year. X sequentially were analytics quarter and process in up sales
XXXX. to full $XX the sales year, an X% For were million, Analytics of increase
we the are year analytical analytics, were We had traction In which for lines, challenging seeing good solid overall. for a FlowVPX fast-growing and environment year. an equipment XX% thanks order overall product to very and our RPM for up
in quarter momentum, sales XXXX. highest with revenue the this X. to XX% we experienced history for both have quarter analytics to X% expect the for and of happy orders are growth We of And that business in
Jason in was I regional but our the will comment of XXXX. section, his speak China one performance to will that in key headwinds
We XXXX, and on sales planning being flat region. optimistic in are about we this currently long-term growth our China to remain potential
of rest the XXXX with full up upside, the Pac Asia XX%. well On performed year sales in
digits, the to our exchange XXXX expect weakest potential than our to double grow strongest. norms, track and low excluding is first Pacing Transitioning the foreign outlook, impact. and QX with half revenue we quarter expected half to is second that QX being stronger COVID our historical to
excluding million of XX% year the X% on in full guidance to up reported to COVID. XXX and XX%, Our to USD a range basis XXX USD up for million, XXXX is XX%
is with product commercial confidence in gives To our strategic center over number deliver we on is growth accelerating traction achieving targets. in Number priorities results, accounts in at these on combined better with innovation and key our maintaining the two best-in-class Asia. our order will and high great our capitalizing team the and one R&D. above-market by market a growth improving stronger quarters, investment increased environment on experience last focusing and following: X and management accelerated us customer The XXXX had further
this in [indiscernible] beginning year. business the of launched already our We at analytics
maintaining for the positioning strengthen ourselves modalities acquire fit achieving We XXX a significantly in X productivity pricing on will further for position new our mixers focused to future. single-use as also new ligands Number be combining and to finally, businesses bigger our growth discipline not-too-distant be our margins XXX on by And to RPS is modalities. new X three focus to number our five ambition PAT. to and four our points, well Number business is targets. becoming launch with several increasing basis a and and further as is particularly resins
office focus key We'll creating enter In also a tools key projects. our management summary, EBITDA-generating on management integration, excited and our M&A other and including project program, we XXXX. consolidation strategic for we're implementing human site as resources manage to key
upon right a products the great have market We to of environment goals. priorities and our and team, combination deliver
identify us act on differentiated sheet we that M&A Our will complement to strong balance enable our portfolio. our ambition technologies unique can as
forward progress to delivering this new and We updating a reward for plan year. have clear you long-term on our for shareholders our through look
on over Jason Now I'd to like to turn performance. financial the call report for a our
